18.75
-1.57%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sinocare
Its shares trade on Shenzhen under the ticker 300298.SZ. It has been listed since 19 March 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.66bn and net income of CN¥92.6m. At that date it held total assets of CN¥5.96bn and shareholders' equity of CN¥3.11bn.
Sinocare, Inc. engages in the development, production, and sale of chronic disease rapid detection products. The company is headquartered in Changsha, Hunan. The company went IPO on 2012-03-19. The firm mainly provides micro blood instant blood sugar monitoring systems including blood sugar testing instruments and related blood sugar testing strips, as well as blood sugar testing systems and mobile blood sugar instruments, among others. The firm also provides diabetes management information systems. The company distributes its products within domestic market and to overseas markets under the brand name of SANNUO.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Mar 2012
- Employees
- 3,756
- Website
- sinocare.com ↗
Leadership
Pay as last reported
- Mr. Shaobo LiChairman of the Board, General ManagerCN¥324,600
- Ms. Xinyi LiVice Chairman of the Board, since 2022
- Mr. Zhuzi HeChief Financial Officer
- Ms. Jiyun ZhengDeputy General Manager, Secretary of the Board
- Mr. Jianwen CaiDeputy General ManagerCN¥1.5m
- Mr. Shimin WangDeputy General Manager, since 2013CN¥306,100
- Ms. Hongjing CheDirectorCN¥120,000
- Mr. Hui LiDirectorCN¥120,000
- Ms. Jizheng ChenIndependent Director
- Mr. Xixiong KangIndependent DirectorCN¥120,000
- Mr. Hong YuanIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sinocare Inc employs 3756 full-time employees in Changsha, Hunan.
- Sinocare Inc offers micro blood instant blood sugar monitoring systems in China and overseas markets.
- Sinocare Inc provides diabetes management information systems for chronic disease detection.
Weaknesses
- Sinocare Inc's products are limited to chronic disease rapid detection in the Health Care sector.
- Sinocare Inc's business is concentrated in the domestic market and SANNUO brand overseas.
- Sinocare Inc's IPO was in 2012, which may indicate limited recent market expansion.
Opportunities
- Sinocare Inc can expand its SANNUO brand in overseas markets beyond current reach.
- Sinocare Inc can leverage its 3756 employees for further product development in Health Care.
- Sinocare Inc can grow its diabetes management information systems in the domestic market.
Threats
- Sinocare Inc faces competition from other Health Care companies in chronic disease detection.
- Sinocare Inc's reliance on the domestic market may limit growth potential.
- Sinocare Inc's products are specific to chronic disease detection, which could be affected by market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.